Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling

Conclusions: Our data demonstrate AEBP1 as a new druggable target in GBM and ACT001 as a potential therapeutic option for improving the clinical treatment of GBM in combination with SHP099.

Source: Theranostics - January 15, 2021 Category: Molecular Biology Authors: Yanli Hou, Bowen Sun, Wenxue Liu, Bo Yu, Qiqi Shi, Fei Luo, Yongrui Bai, Haizhong Feng Tags: Research Paper Source Type: research